Literature DB >> 13680284

Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression.

S Lassmann1, M Bauer, R Rosenberg, H Nekarda, R Soong, R Rüger, H Höfler, M Werner.   

Abstract

BACKGROUND AND AIMS: Evaluation of cytokeratin 20 (CK20) specific quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) and immunohistochemistry (IHC) for detection of occult tumor cells in lymph nodes of 72 patients with colorectal carcinoma (UICC stage I and II).
METHODS: Serial sections of formalin-fixed, paraffin-embedded lymph nodes (mean 14.3/case) were used for microdissection, RNA isolation and QRT-PCR and for CK20 IHC using routine protocols. Results of QRT-PCR and IHC were compared and correlated to the CK20 expression pattern of the primary tumors and clinical follow-up.
RESULTS: IHC revealed CK20-positive tumor cells in lymph nodes of 14.5% (10/69) and 0% (0/3) cases with a CK20-positive and CK20-negative primary tumor, respectively. CK20 mRNA was detected in the lymph nodes of 36.8% (7/19) cases by QRT-PCR with all 7 cases also expressing CK20 mRNA in the primary tumor. CK20 mRNA (QRT-PCR) and protein (IHC) detection in serial sections did not agree in 25% (5/20) of cases. A trend was seen towards a worse disease course for patients with CK20-positive lymph nodes by IHC (incidence of recurrent disease) and QRT-PCR (disease-free survival, incidence of recurrent disease).
CONCLUSION: CK20-specific IHC and QRT-PCR are supportive tools to conventional histology for detection of occult tumor cells in archival tissues, with the restriction that a laborious QRT-PCR procedure is necessary to achieve appropriate specificity. A prognostic value of CK20 IHC or QRT-PCR for stratification of UICC stage I and II patients into those likely to develop recurrent disease was not evident.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680284     DOI: 10.1007/s00384-003-0530-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  40 in total

1.  Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping.

Authors:  Y Miyake; H Yamamoto; Y Fujiwara; M Ohue; Y Sugita; N Tomita; M Sekimoto; N Matsuura; H Shiozaki; M Monden
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence.

Authors:  M Sanchez-Cespedes; M Esteller; K Hibi; F O Cope; W H Westra; S Piantadosi; J G Herman; J Jen; D Sidransky
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

Review 3.  Molecular detection of micrometastases and circulating tumor cells in solid tumors.

Authors:  R A Ghossein; S Bhattacharya; J Rosai
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

4.  Predictive value of genetic diagnosis for cancer micrometastasis: histologic and experimental appraisal.

Authors:  N Yamamoto; Y Kato; A Yanagisawa; H Ohta; T Takahashi; T Kitagawa
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

5.  The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas.

Authors:  R Moll; R Zimbelmann; M D Goldschmidt; M Keith; J Laufer; M Kasper; P J Koch; W W Franke
Journal:  Differentiation       Date:  1993-06       Impact factor: 3.880

6.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

7.  Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20.

Authors:  D K Wyld; P Selby; T J Perren; S K Jonas; T G Allen-Mersh; J Wheeldon; S A Burchill
Journal:  Int J Cancer       Date:  1998-06-19       Impact factor: 7.396

8.  Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.

Authors:  R A Ghossein; H I Scher; W L Gerald; W K Kelly; T Curley; A Amsterdam; Z F Zhang; J Rosai
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

9.  Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay.

Authors:  D S Hoon; Y Wang; P S Dale; A J Conrad; P Schmid; D Garrison; C Kuo; L J Foshag; A J Nizze; D L Morton
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

10.  Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction.

Authors:  S A Burchill; M F Bradbury; K Pittman; J Southgate; B Smith; P Selby
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more
  10 in total

1.  Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method.

Authors:  Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients.

Authors:  Berrin Tunca; Gulcin Tezcan; Gulsah Cecener; Unal Egeli; Abdullah Zorluoglu; Tuncay Yilmazlar; Secil Ak; Omer Yerci; Ersin Ozturk; Gorkem Umut; Turkkan Evrensel
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-16       Impact factor: 4.553

3.  Previstage GCC test for staging patients with colorectal cancer.

Authors:  Alex Mejia; Scott A Waldmana
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

4.  Detection of disseminated tumor cells in the lymph nodes of colorectal cancer patients using a real-time polymerase chain reaction assay.

Authors:  Erkki Lotspeich; Markus Schoene; Heinz Gerngross; Roland Schmidt; Reinhard Steinmann; Marco Ramadani; Susanne Gansauge
Journal:  Langenbecks Arch Surg       Date:  2007-04-25       Impact factor: 3.445

5.  Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use?

Authors:  Michael Conzelmann; Ulrich Linnemann; Martin R Berger
Journal:  Int J Colorectal Dis       Date:  2004-09-30       Impact factor: 2.571

6.  The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR.

Authors:  Oddmund Nordgård; Satu Oltedal; Hartwig Kørner; Ole Gunnar Aasprong; Kjersti Tjensvoll; Bjørnar Gilje; Reino Heikkilä
Journal:  Int J Colorectal Dis       Date:  2009-01-03       Impact factor: 2.571

Review 7.  Lymph node staging in colorectal cancer: old controversies and recent advances.

Authors:  Annika Resch; Cord Langner
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

8.  Prognostic significance of Cytokeratin 20-positive lymph node vascular endothelial growth factor A mRNA and chromodomain helicase DNA binding protein 4 in pN0 colorectal cancer patients.

Authors:  Sze Chuen Cesar Wong; Moon Tong Cheung; Lewis Lai Yin Luk; Vivian Ha Man Lee; Pak Tat Chan; Hin Fung Andy Tsang; Evelyn Yin Kwan Wong; Vivian Weiwen Xue; Amanda Kit Ching Chan; John Kwok Cheung Chan
Journal:  Oncotarget       Date:  2017-12-19

9.  Effect of mesenchymal stem cells on cytochrome-c release and inflammation in colon cancer induced by 1,2-dimethylhydrazine in Wistar albino rats.

Authors:  Afrah F Alkhuriji; Seham G Alsaiari; Suliman Y Alomar; Alaa A Alnafjan; Hussah Alobaid; Manal F El-Khadragy
Journal:  Biosci Rep       Date:  2021-03-26       Impact factor: 3.840

10.  CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients.

Authors:  J Harder; V Engelstaedter; H Usadel; S Lassmann; M Werner; P Baier; F Otto; M Varbanova; E Schaeffner; M Olschewski; H E Blum; O G Opitz
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.